Ticker Details
Xencor, Inc. Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
IPO Date:	December 3, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$814.79M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.55 | 2.33%
Avg Daily Range (30 D):	$0.34 | 2.70%
Avg Daily Range (90 D):	$0.43 | 3.03%

Institutional Daily Volume
Avg Daily Volume:	.28M
Avg Daily Volume (30 D):	.4M
Avg Daily Volume (90 D):	.65M

Trade Size
Avg Trade Size (Sh.):	69
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	65

Institutional Trades
Total Institutional Trades:	3,211
Avg Institutional Trade:	$1.99M
Avg Institutional Trade (30 D):	$1.53M
Avg Institutional Trade (90 D):	$2.03M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.25M
Avg Closing Trade (30 D):	$1.64M
Avg Closing Trade (90 D):	$2.44M
Avg Closing Volume:	91.03K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 6, 2025 @ 8:13 PM Xencor (XNCR) Q2 Revenue Jumps 82% Source: Not Specified

Jul 16, 2025 @ 4:30 AM [Latest] Global Ultomiris Drug Market Size/Share W... Source: Custom Market Insights

Sep 12, 2024 @ 5:09 PM Xencor Surges 10.5%: Is This an Indication of Furt... Source: Zacks

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.08	$-.41
Diluted EPS		$-.08	$-.41
Revenue		$21M	$43.61M
Gross Profit
Net Income / Loss		$-6.03M	$-30.83M
Operating Income / Loss		$-47.52M	$-33.17M
Cost of Revenue
Net Cash Flow		$-16.15M	$4.77M
PE Ratio